Research Article
Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers
Table 3
Assay of p53 antibody, CEA, and CA19-9.
| | Pancreatic cancer | Biliary tract cancer | Pancreatobiliary cancer | | Mean ± SD*1 | CV*2 | Mean ± SD*1 | CV*2 | Mean ± SD*1 | CV*2 |
| p53 antibody (U/mL) | 0.716 ± 0.30 | 0.42 | 0.716 ± 0.42 | 0.59 | 0.716 ± 0.31 | 0.44 | CEA (ng/mL) | 38.33 ± 146.8 | 3.83 | 21.42 ± 25.0 | 1.16 | 34.01 ± 127.05 | 3.73 | CA19-9 (U/L) | 3142.9 ± 9146.8 | 2.91 | 5859.8 ± 16446.5 | 2.79 | 3836.6 ± 11311.7 | 2.94 |
|
|
SD: standard deviation. CV: coefficient of variation.
|